Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Drug-resistant tuberculosis (TB) poses a significant global health challenge.
• Pyrazinamide (PZA) resistance in Mycobacterium tuberculosis (Mtb) strains limits treatment options.
• New therapeutic strategies, including analog development and direct lung delivery, are crucial for combating MDR and XDR-TB.

Purpose of the Study:

• To evaluate the efficacy of pyrazinoic acid esters (PAEs), PZA analogs, delivered via aerosol for treating TB.
• To assess PAEs as a potential treatment for PZA-resistant Mtb strains.
• To investigate novel drug delivery methods for TB therapy.

Main Methods:

• PAEs were administered daily as aqueous dispersions using a vibrating mesh nebulizer to guinea pigs infected with Mtb.
• The aerosolized PAEs were given over 4 weeks as part of a regimen including oral first-line TB drugs.
• Organ bacterial burden was measured to assess treatment efficacy.

Main Results:

• PAE aerosol therapy, when used as a supplement to oral treatment, significantly reduced bacterial burden in organs compared to untreated controls.
• This indicates PAE aerosol therapy is a potentially significant addition for treating PZA-resistant MDR-TB and XDR-TB.
• Low-dose oral PZA combined with standard therapy also showed reduced bacterial burden, suggesting relevance for PZA-susceptible TB.

Conclusions:

• The study provides justification for further investigation into PZA analogs and their lung delivery for TB treatment.
• PAE aerosol therapy represents a promising new strategy for managing drug-resistant TB.
• Novel drug delivery methods are essential for improving TB treatment outcomes.